


AMENDED CLAIM SET:

1. (cancelled).

2. (currently amended) ~~The compound of according to claim 1, being a 1,2,4-~~
benzothiadiazine derivative of the formula; ~~having the general formula (II)~~



wherein

R³ represents hydrogen, cycloalkyl, cycloalkylalkyl, alkyl, haloalkyl, alkoxy, a carbocyclic 7- to 10-membered ring, a heterocyclic 5- to 6-membered ring, or benzyl; or R³ together with R⁴ forms a 5- to 6-membered ring; and

R⁴ represents hydrogen, or alkyl, or R⁴ together with R³, and together with the atoms to which they are attached, forms a 5- to 6-membered ring, which ring is optionally substituted one or more times with substituents selected from halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, amino, and thio, and optionally containing one or more heteroatoms and optionally containing carbonyl groups; and

R⁵ represents hydrogen, halogen, alkyl, alkenyl, alkynyl, phenyl, or -SO₂-NR¹¹R¹²; wherein R¹¹ and R¹² independently represents hydrogen, alkyl, cycloalkyl, benzyl, or aryl; or R¹¹ and R¹², together with the nitrogen to which they are attached, form a heterocyclic 5- to 6-membered ring structure; and

R⁶ represents hydrogen, Br, F, I, cycloalkyl, or alkyl, alkoxy, or alkoxyalkyl; or R⁶ represents phenyl, which phenyl is optionally substituted one or more times with substituents selected from the group consisting of alkyl, and alkoxy; or R⁶ represents HET; or R⁶ represents -S-R¹⁵, -SO-R¹⁵, -SO₂-R¹⁵, -SO₂OR¹⁵, -SO₂-NR¹⁵R¹⁶, -NHCOR¹⁵, -CONR¹⁵R¹⁶, -CR¹⁵=NOR¹⁵, -CO-R¹⁵, or -CO₂-R¹⁵, wherein R¹⁵ and R¹⁶ independently represents hydrogen, alkyl, cycloalkyl,

phenyl, or benzyl; and R^{15} and R^{16} independently represents hydrogen, alkyl, cycloalkyl, benzyl, or aryl; or R^{15} and R^{16} , together with the nitrogen to which they are attached, form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, amino or thio, phenyl, benzyl, $-SO_2$ -alkyl, $-SO_2$ -aryl, $-SO_2$ -benzyl; and optionally the heterocyclic ring is fused to an aryl; and

R^7 represents Br, F, I, alkyl, cyano, cyanoalkyl, nitroalkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, cyclohaloalkyl, $-(alkyl)_m-NR^{17}R^{18}$, $-NHSO_2R^{17}$, $-SR^{17}$, $-SO_2R^{17}$, $-SO_2R^{17}$, $-SO_2OR^{17}$, $-NHCOR^{17}$, $-CONR^{17}R^{18}$, $-CR^2=NOR^{17}$, $-CO_2R^{17}$; wherein R^2 and R^{17} independently represents hydrogen, alkyl, cycloalkyl, phenyl, or benzyl; and R^{17} and R^{18} independently represents hydrogen, alkyl, cycloalkyl, benzyl, or aryl; or R^{17} and R^{18} , together with the nitrogen to which they are attached, form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with alkyl, $-SO_2$ -alkyl, $-SO_2$ -aryl, $-SO_2$ -benzyl, and optionally the heterocyclic ring is fused to an aryl; or R^7 represents $-(alkyl)_m-SO_2-NR^{17}R^{18}$, $-SO_2-NR^{17}R^{18}$, wherein m is 0 or 1; and R^{17} and R^{18} independently of each another represent hydrogen or alkyl, represents alkyl, cycloalkyl, benzyl, or aryl; or R^{17} and R^{18} together with the nitrogen to which they are attached form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, amino, thio, aryl, benzyl, $-SO_2$ -alkyl, $-SO_2$ -aryl, or $-SO_2$ -benzyl, and optionally the heterocyclic ring is fused to an aryl; or R^7 represents HET, which HET is optionally substituted one or more times with substituents selected from halogen, alkyl, phenyl, and $-SO_2NR^{17}R^{18}$; or R^7 represents phenyl, which phenyl is optionally substituted one or more times with substituents selected from the group consisting of alkyl, hydroxy, alkoxy, halogen, haloalkyl, amino, $-NHCO$ -alkyl, nitro, $-OCF_3$, or $-SO_2-NR^{17}R^{18}$; wherein R^{17} and R^{18} independently represents hydrogen, alkyl, cycloalkyl, benzyl, or aryl; or R^{17} and R^{18} , together with the nitrogen to which they are attached, form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with halogen, alkyl, $-SO_2$ -alkyl, $-SO_2$ -aryl, $-SO_2$ -benzyl, and optionally the heterocyclic ring is fused to an aryl; or R^7 together with R^6 , or together with R^8 , forms a 5- to 7-membered ring having the one of the following structures $-O-(CH_2)_n-O-$, wherein n is 1, 2 or 3; $-SO_2-NR-(CH_2)_n-$, wherein R is hydrogen, alkyl, cycloalkyl, benzyl or aryl, and n is 1 or 2; $-SO-NR-(CH_2)_n-$, wherein R is hydrogen, alkyl, cycloalkyl, benzyl or aryl, and n is 1 or 2; $-SO_2-$

$(CH_2)_n$, wherein n is 2 or 3; $SO(CH_2)_n$, wherein n is 2 or 3; $CO-CH=CH-NH$; $CO-CH=CH-O$; $CO-(CH_2)_n-NH$, wherein n is 1 or 2; $CO-NH-(CH_2)_n$, wherein n is 1 or 2; $CO-(CH_2)_2-O$; or $O-(CH_2)_n-O$, wherein n is 1, 2 or 3; and

R^8 represents hydrogen[[.]] or alkyl, alkoxy, hydroxyalkyl, halogen, haloalkyl, CN, cyanoalkyl, nitro, or nitroalkyl; or R^8 represents phenyl, which phenyl is optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, and alkoxy; or R^8 represents HET ; or R^8 represents $-S-R^{19}$, $-SO-R^{19}$, $-SO_2-R^{19}$, $-SO_2OR^{19}$, $-SO_2-NR^{19}R^{20}$, $-NHCOR^{19}$, $-CONR^{19}R^{20}$, $-CR'=NOR^{19}$, $-CO-R^{19}$, or $-CO_2-R^{19}$, wherein R^{19} and R^{20} independently represents hydrogen, alkyl, cycloalkyl, phenyl, or benzyl; and R^{19} and R^{20} independently represents hydrogen, alkyl, cycloalkyl, benzyl, or aryl; or R^{19} and R^{20} , together with the nitrogen to which they are attached, form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, amino or thio, phenyl, benzyl, $-SO_2$ -alkyl, $-SO_2$ -aryl, $-SO_2$ -benzyl, and optionally the heterocyclic ring is fused to an aryl.

3. - 7. (cancelled).

8. (currently amended) The 1,2,4-benzothiadiazine derivative of claim 2, compound according to claim 1 wherein R^7 represents halogen, alkyl, cyano, cyanoalkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, cyclohaloalkyl, $-(alkyl)_m-NR^{17}R^{18}$, $-NHSO_2-R^{17}$, $-S-R^{17}$, $-SO-R^{17}$, $-SO_2-R^{17}$, $-SO_2OR^{17}$, $-NHCOR^{17}$, $-CONR^{17}R^{18}$, $-CR'=NOR^{17}$, $-CO-R^{17}$, or $-CO_2-R^{17}$, wherein R^{17} and R^{18} independently represents hydrogen, alkyl, cycloalkyl, phenyl, or benzyl; and R^{17} and R^{18} independently represents hydrogen, alkyl, cycloalkyl, benzyl, or aryl; or R^{17} and R^{18} , together with the nitrogen to which they are attached, form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with alkyl, $-SO_2$ -alkyl, $-SO_2$ -aryl, $-SO_2$ -benzyl, and optionally the heterocyclic ring is fused to an aryl; or R^7 represents $-(alkyl)_m-SO_2-NR^{17}R^{18}$, $-SO_2-NR^{17}R^{18}$, wherein m is 0 or 1; and R^{17} and R^{18} independently represent hydrogen or alkyl represents alkyl, cycloalkyl, benzyl, or aryl; or R^{17} and R^{18} , together with the nitrogen to which they are attached, form a heterocyclic 3- to 8-membered ring

structure, which ring structure is optionally substituted with alkyl, SO_2 -alkyl, SO_2 -aryl, or SO_2 -benzyl, and optionally the heterocyclic ring is fused to an aryl; or R^7 represents HET, which HET is optionally substituted one or more times with substituents selected from halogen, alkyl, phenyl, or $\text{SO}_2\text{NR}^{17}\text{R}^{18}$, wherein R^{17} and R^{18} independently represents hydrogen, alkyl, cycloalkyl, benzyl, or aryl; or R^{17} and R^{18} , together with the nitrogen to which they are attached, form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with halogen, alkyl, SO_2 -alkyl, SO_2 -aryl, or SO_2 -benzyl, and optionally the heterocyclic ring is fused to an aryl; or R^7 represents phenyl optionally substituted one or more times with substituents selected from the group consisting of alkyl, hydroxy, alkoxy, halogen, haloalkyl, amino, NHCO -alkyl, nitro, OCF_3 , $\text{SO}_2\text{-NR}^{17}\text{R}^{18}$, wherein R^{17} and R^{18} independently represents hydrogen, alkyl, cycloalkyl, benzyl, or aryl; or R^{17} and R^{18} , together with the nitrogen to which they are attached, form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with halogen, alkyl, SO_2 -alkyl, SO_2 -aryl, or SO_2 -benzyl, and optionally the heterocyclic ring is fused to an aryl; or R^7 together with R^6 , or together with R^8 , forms a 5- to 7-membered ring having the one of the following structures $\text{O}-(\text{CH}_2)_n\text{-O}$, wherein n is 1, 2 or 3; $\text{SO}_2\text{-NR}(\text{CH}_2)_n$, wherein R is hydrogen, alkyl, cycloalkyl, benzyl or aryl, and n is 1 or 2; $\text{SO-NR}(\text{CH}_2)_n$, wherein R is hydrogen, alkyl, cycloalkyl, benzyl or aryl, and n is 1 or 2; $\text{SO}_2-(\text{CH}_2)_n$, wherein n is 2 or 3; $\text{SO}-(\text{CH}_2)_n$, wherein n is 2 or 3; CO-CH=CH-NH ; CO-CH=CH-O ; $\text{CO}-(\text{CH}_2)_n\text{-NH}$, wherein n is 1 or 2; $\text{CO-NH}-(\text{CH}_2)_n$, wherein n is 1 or 2; $\text{CO}-(\text{CH}_2)_2\text{-O}$; or $\text{O}-(\text{CH}_2)_n\text{-O}$, wherein n is 1, 2 or 3.

9. (cancelled).

10. (currently amended) The 1,2,4-benzothiadiazine derivative of claim 2, compound according to claim 1 wherein X represents SO_2 ; and Y represents N; and R^2 represents H; and R^3 represents cycloalkyl, a carbocyclic 7- to 10-membered ring, a heterocyclic 5- to 6-membered ring; and

R^4 represents H; and

R^5 represents H; and

R^6 represents hydrogen[,], or alkyl or halogen; and

R^7 represents eyanoalkyl, nitroalkyl, haloalkyl, or $-(alkyl)_m-SO-R^{17}$, $-(alkyl)_m-SO_2-R^{17}$, $-(alkyl)_m-SO_2-NR^{17}R^{18}$, $-SO_2-NR^{17}R^{18}$, $-(alkyl)_m-CR^2=NOR^{17}$, $-(alkyl)_m-CO-R^{17}$, or $-(alkyl)_m-CO_2-R^{17}$; wherein m is 0 or 1; and R^2 and R^{17} independently represents hydrogen, alkyl, cycloalkyl, phenyl, or benzyl; and R^{17} and R^{18} independently represent hydrogen or alkyl represents alkyl, cycloalkyl, benzyl, or aryl; or R^{17} and R^{18} , together with the nitrogen to which they are attached, form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with alkyl, $-SO_2$ -alkyl, $-SO_2$ -aryl, or $-SO_2$ -benzyl, and optionally the heterocyclic ring is fused to an aryl; or R^7 represents $-(alkyl)_m-SO_2-NR^{17}R^{18}$, wherein m is 0 or 1; and R^{17} and R^{18} independently represents alkyl, cycloalkyl, benzyl, or aryl; or R^{17} and R^{18} , together with the nitrogen to which they are attached, form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with alkyl, $-SO_2$ -alkyl, $-SO_2$ -aryl, or $-SO_2$ -benzyl, and optionally the heterocyclic ring is fused to an aryl; or R^7 represents HET; or R^7 together with R^6 , or together with R^8 , forms a 5- to 7 membered ring having the one of the following structures $-O-(CH_2)_n-O-$, wherein n is 1, 2 or 3; $-SO_2-NR-(CH_2)_n-$, wherein R is hydrogen, alkyl, cycloalkyl, benzyl or aryl, and n is 1 or 2; $-SO-NR-(CH_2)_n-$, wherein R is hydrogen, alkyl, cycloalkyl, benzyl or aryl, and n is 1 or 2; $-SO_2-(CH_2)_n-$, wherein n is 2 or 3; $-SO-(CH_2)_n-$, wherein n is 2 or 3; $-CO-CH=CH-NH-$; $-CO-CH=CH-O-$; $-CO-(CH_2)_n-NH-$, wherein n is 1 or 2; $-CO-NH-(CH_2)_n-$, wherein n is 1 or 2; $-CO-(CH_2)_2-O-$; or $-O-(CH_2)_n-O-$, wherein n is 1, 2 or 3; and

R^8 represents alkyl, halogen, eyanoalkyl, nitroalkyl, haloalkyl, $-(alkyl)_m-SO-R^{17}$, $-(alkyl)_m-SO_2-R^{17}$, $-(alkyl)_m-SO_2-NR^{17}R^{18}$, $-(alkyl)_mCONR^{17}R^{18}$, $-(alkyl)_m-CR^2=NOR^{17}$, $-(alkyl)_m-CO-R^{17}$, or $-(alkyl)_mCO_2-R^{17}$; wherein m is 0 or 1; R^2 and R^{17} independently represents hydrogen, alkyl, cycloalkyl, phenyl, or benzyl; and R^{17} and R^{18} independently represents hydrogen, alkyl, cycloalkyl, benzyl, or aryl; or R^{17} and R^{18} , together with the nitrogen to which they are attached, forms a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with alkyl, $-SO_2$ -alkyl, $-SO_2$ -aryl, or $-SO_2$ -benzyl, and optionally the heterocyclic ring is fused to an aryl; or R^8 represents HET.

11. (currently amended) The 1,2,4-benzothiadiazine derivative of claim 2, compound according to claim 1 wherein R^3 represents hydrogen, cyclopropyl, cyclopentyl, $[(,)]$ or

cyclohexyl, methyl, ethyl, propyl, isopropyl, CF₃, ethoxy, norbornene, norbornane, adamantane, or benzyl; or R³ together with R⁴, and together with the atoms to which they are attached, forms a 5-membered ring.

12. (cancelled).

13. (cancelled).

14. (currently amended) The 1,2,4-benzothiadiazine derivative of claim 2, compound of Formula I, according to claim 1 wherein R⁶ represents hydrogen, 2-methoxyphenyl, 2-pyridyl, 3-pyridyl, or methyl, methoxy, chloro or bromo.

15. (currently amended) The 1,2,4-benzothiadiazine derivative of claim 2, compound of Formula I according to claim 1 wherein R⁷ represents chloro, bromo, methyl, 1-hydroxyethyl, acetyl, (CH₃)C=N-OH, CONH₂, CO₂-ethyl, cyano, phenyl, 2-N-acetylaminophenyl, 2-nitrophenyl, 2-methoxyphenyl, 4-trifluoromethyl-2-methoxyphenyl, 2,4-dimethoxyphenyl, 2-N,N-dimethylsulfamoylphenyl, 2-chlorophenyl, 2-fluorophenyl, 3-hydroxyphenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-furyl, 3-furyl, 2-thienyl, 2-(N-methyl)imidazolyl, 5-triazolyl, 4-phenyl-triazol-5-yl, 5-methyl-1,2,4-oxadiazol-3-yl, CH₃CONH-, CH₃SO₂NH-, SO₂OH-, phenyl-SO₂-, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-phenyl-N-methyl-sulfamoyl, or -SO₂-heterocyclic ring, wherein the heterocyclic ring is rings are selected from the group of piperidine, pyrrolidine, 1,2,5,6-tetrahydropyridine, tetrahydroquinoline, N-methylpiperazine, N-sulfonylmethyl-piperazine, and morpholine.

16. (cancelled).

17. (cancelled).

18. (withdrawn - currently amended) The 1,2,4-benzothiadiazine derivative of claim 2, compound of Formula I according to claim 1 wherein X is C=O; and Y is N, O or CH; and R³ represents hydrogen; and

R³ represents hydrogen, CH₃, CF₃, cyclohexyl, norbornene, phenyl, or ethyl; and

R⁷ represents hydrogen, N,N-dimethylsulfamoyl, N-cyclohexylsulfamoyl, tetrahydropyrid-1-yl-sulfuric acid, morpholin-4-yl-sulfuric acid, sulfamoyl, bromo; and

R⁵, represents hydrogen or bromo; and R⁴, R⁶, and R⁸ all represent hydrogen.

19. – 21. (cancelled).

22. (currently amended) The 1,2,4-benzothiadiazine derivative according to claim 2, said compound being:

3-Bicyclo[2.2.1]hept-5'-en-2'-yl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

1,2,3,5,10,10a-Hexahydrobenzo[e]pyrrolo[1,2-b]-1,2,4-thiadiazine-5,5-dioxide;

3-Cyclohexyl-6-(2-methoxyphenyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-6-(2-pyridyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-6-(3-pyridyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-(1-hydroxyethyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-acetyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-(1-hydroxyiminoethyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-carbamoyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-ethoxycarbonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-cyano-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Bicyclo[2.2.1]hept-5'-en-2'-yl-7-phenyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-(2'-acetamidophenyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-(2'-nitrophenyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-(2'-methoxyphenyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

- 3-Cyclohexyl-7-(2'-methoxy-4'-trifluoromethylphenyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(2',4'-dimethoxyphenyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(2'-(*N,N*-dimethylsulfamoyl)phenyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(2'-chlorophenyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(2'-fluorophenyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(3'-hydroxyphenyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(2'-pyridyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(3'-pyridyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(2'-pyrimidinyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(2'-furyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(3'-furyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(2'-thienyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(1-methyl-1*H*-2-imidazolyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(1',2',3'-triazol-4'-yl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(5'-phenyl-1',2',3'-triazol-4'-yl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(5'-methyl-1',2',4'-oxadiazol-3-yl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-acetamido-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-methylsulfonylamino-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-phenylsulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 2-Cyclohexyl-1,2,3,4-tetrahydro-6-quinazoline-sulfonamide;
- 3-Methyl-7-dimethylsulfamoyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 2-Cyclohexyl-1,2,3,4-tetrahydro-6-quinazoline-*N,N*-dimethylsulfonamide;

- 3-Cyclohexyl-7-dimethylaminosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(*N,N*-diethylamino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-pyrrolidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Methyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclopropyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Isopropyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-propyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Benzyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclopentyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Bicyclo[2.2.1]hept-5'-en-2'-yl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(1',2',3',6'-tetrahydropiperidino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(*N*-methyl-*N*-phenylamino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(1'-(1',2',3',4'-tetrahydroquinolinyl))sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(4'-methylpiperazino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-(4'-methylsulfonylpiperazino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-7-morpholinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Methyl-7-dimethylsulfamoyl-1,2-dihydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Methyl-7-(1',2',3',6'-tetrahydropiperidino)sulfonyl-1,2-dihydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Trifluoromethyl-7-dimethylsulfamoyl-1,2-dihydro-1,2,4-benzothiadiazine-1,1-dioxide;
- 3-Cyclohexyl-8-methyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-8-hydroxymethyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
3-Cyclohexyl-8-(2-methoxyphenyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
3-Cyclohexyl-8-(3-methoxyphenyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
3-Cyclohexyl-8-(2-pyridyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
3-Cyclohexyl-8-methoxy-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
5,7-Dibromo-1,2-dihydro-1,2,4-benzothiadiazine-1,1-dioxide;
3-Cyclohexyl-2-methyl-7-morpholinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
3-Cyclohexyl-4-methyl-7-morpholinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
7-Methylsulfonylamino-1,2,3,3a,4,5-hexahydrobenzo[e]pyrrolo[2,1-c]-1,2,4-thiadiazine-5,5-dioxide;
7-Sulfamoyl-1,2,3,3a,4,5-hexahydrobenzo[e]pyrrolo[2,1-c]-1,2,4-thiadiazine-5,5-dioxide;
7-Methylsulfamoyl-1,2,3,3a,4,5-hexahydrobenzo[e]pyrrolo[2,1-c]-1,2,4-thiadiazine-5,5-dioxide;
7-Dimethylsulfamoyl-1,2,3,3a,4,5-hexahydrobenzo[e]pyrrolo[2,1-c]-1,2,4-thiadiazine-5,5-dioxide;
7-Dimethylsulfamoyl-1,2,3,5-tetrahydrobenzo[e]pyrrolo[2,1-c]-1,2,4-thiadiazine-5,5-dioxide;
7-(1',2',3',6'-Tetrahydropiperidino)sulfonyl-1,2,3,5-tetrahydrobenzo[e]pyrrolo[2,1-c]-1,2,4-thiadiazine-5,5-dioxide;
3-Bicyclo[2.2.1]hept-5'-en-2'-yl-5,7-dimethyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
3-Cyclohexyl-7-(N,N-diethylsulphamoyl)-5-methyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
3-Bicyclo[2.2.1]hept-5'-en-2'-yl-5,7-diphenyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
3-Cyclohexyl-6-methyl-7-(2'-pyridyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;
3-Cyclohexyl-6-methyl-7-(4'-triazolyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclopentyl-6-methyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothia-diazine-1,1-dioxide;

3-Cyclohexyl-6-methyl-7-morpholinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-6-(2-methoxyphenyl)-7-methyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-6-methoxy-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothia-diazine-1,1-dioxide;

3-Cyclohexyl-7,8-ethylenedioxy-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-6,7-ethylenedioxy-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

or

3-Cyclohexyl-7-sulfamoyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Isobutyl-8-(piperidinosulfonyl)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-1,1-dioxide;

or a pharmaceutical acceptable salt thereof.

23. (cancelled).

24. (currently amended) A pharmaceutical composition comprising an effective amount of a 1,2,4-benzothiadiazine derivative chemical compound according to claim 2 [[1]], or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable excipient, carrier or diluent.

25. – 27. (cancelled).

28. (withdrawn - currently amended) A method of treating a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to modulation of the AMPA receptor complex of the central nervous system, which method comprises administration of a therapeutically effective amount of a 1,2,4-benzothiadiazine derivative chemical compound according to claim 2 [[1]].

29. (withdrawn) The method according to claim 28, wherein the disorder or disease is responsive to modulation of the AMPA receptor complex of the central nervous system.

30. (withdrawn) The method according to claim 28, wherein the disorder or disease is selected from memory and learning disorders, psychotic disorder, sexual dysfunction, intellectual impairment disorders, schizophrenia, depression, autism, Alzheimer's disease, learning deficit, attention deficit, memory loss, and senile dementia; or from a disorder or disease resulting from trauma, stroke, epilepsy, Alzheimer's disease, neurotoxic agents, aging, neurodegenerative disorder, alcohol intoxication, substance abuse, cardiac bypass surgery, and cerebral ischemia.

31. (cancelled).

32. (withdrawn - currently amended) A method of treating a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to modulation of the AMPA receptor complex of the central nervous system, which method comprises administration of a therapeutically effective amount of a 1,2,4-benzothiadiazine derivative chemical compound according to claim 2 [[1]].

33. (currently amended) The 1,2,4-benzothiadiazine derivative compound of claim 22, which is

3-cyclopentyl-6-methyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide; or a pharmaceutically acceptable salt thereof.